Jessica Mantilla, MD
Infectious Disease · Glendale, CANPI 1891957973
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 87.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $4,043 and has fallen 84.5% since, to $627 in 2025.
Across 128 payments — averaging $71.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Merck$600
- Paratek Pharmaceuticals, Inc.$251
- Shionogi Inc$227
- Tetraphase Pharmaceuticals, Inc.$88
What the payments were for
- Speaking & faculty fees$4,70051%
- Travel & lodging$6347%
- Food & beverage$3,73841%
- Education$1171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 109 | $8,022 |
| Merck | 9 | $600 |
| Paratek Pharmaceuticals, Inc. | 5 | $251 |
| Shionogi Inc | 4 | $227 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $88 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,188 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levofloxacin | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Glendale
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
- Shawn HasslerSan Francisco$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.